Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
← catalyst calendarNCT07488884 · readout in 286 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-01 | estimated | When the study began enrolling |
| Primary completion | 2027-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Cancer Resectable
- Pancreatic Cancer
Interventions
- Drug: Nogapendekin Alfa Inbakicept (N803) — also filed as N-803, ANKTIVA
- Drug: Sotevtamab
- Drug: Zabadinostat (CXD101)
- Drug: Nab paclitaxel / gemcitabine
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured From first dose through 30 days after last dose (SAEs and immune-related AEs followed for 90 days after last dose); survival/safety follow-up through 104 weeks (2 years) post last dose.
Clinically important changes in laboratory tests and vital signs
measured Baseline (pre-dose) through 30 days after last dose (clinically important labs/vitals and related actions); SAE/irAE follow-up 90 days; long-term follow-up through 104 weeks (2 years) post last dose.
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed